achillestx.com (ACHL): Prakiraan wutah bathi resik saben saham kanggo taun ngarep

Logo perusahaan publik Achilles Therapeutics plc (ACHL)

Achilles Therapeutics is developing personalized T-cell therapy leveraging PELEUS platform data and bioprinting patents. This GURU.Markets consensus EPS n+1 forecast chart illustrates the current trend, with the latest data point standing at 33.40. High margins on customized solutions offset scaling challenges, while the massive neoantigen market provides significant opportunities to expand the company's partner network.

Achilles Therapeutics (ACHL): Prakiraan wutah bathi resik saben saham kanggo taun ngarep saka 04.07.2022 nganti 29.03.2025

Ringkesan rincian data analitis Achilles Therapeutics PLC (ACHL)

- rega saham lan konsensus proyeksi valuasi:
Analisis fundamental perusahaan:ACHL, Achilles Tx
Produk dadi Achilles Therapeutics plc

For Achilles Therapeutics (ACHL), which is developing personalized cell therapy through scientific collaborations, the trends in the company's EPS forecasts for the coming year reflect the market's valuation of the commercialization of its developments. The dynamics of this metric are based on analysts' consensus expectations for net earnings per share, where sharp deviations in the line signal a revision of the business's fundamental value and risks of a significant price correction.

Perusahaan pesaing